Insider Activity: Barry Feinberg just Acquired 2,000 shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI), be careful if you are short!

November 25, 2016 - By Clifton Ray

Insider Activity: Barry Feinberg just Acquired 2,000 shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI), be careful if you are short!

Barry Feinberg Insider Buy

Biodelivery Sciences International Inc’s director, Barry Feinberg, bought 2,000 shares of stock in the public firm. The average price paid by Barry Feinberg was $1.7, for full purchase worth of $3,338 USD. This is not his first insider trade, in the last 30 days, he purchased another 3,000 shares worth $5,610 USD. This insider trade, was conducted on 25/11/2016. It’s available for a free review at the SEC’s website and can be seen at this page. Right now, Barry Feinberg owns 22,500 shares which are equivalent to roughly 0.04% of Biodelivery Sciences International Inc’s market capitalization.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Out of 5 analysts covering BioDelivery Sciences International (NASDAQ:BDSI), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. $14 is the highest target while $4 is the lowest. The $8 average target is 384.85% above today’s ($1.65) stock price. BioDelivery Sciences International has been the topic of 9 analyst reports since August 16, 2015 according to StockzIntelligence Inc. The stock has “Buy” rating given by William Blair on Sunday, August 16. The stock has “Hold” rating given by Cantor Fitzgerald on Wednesday, May 11. The rating was maintained by Piper Jaffray on Thursday, May 12 with “Overweight”. FBR Capital maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) rating on Tuesday, November 10. FBR Capital has “Mkt Perform” rating and $14 price target. Piper Jaffray initiated BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Monday, February 8 with “Overweight” rating. Janney Capital upgraded BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Friday, September 23 to “Buy” rating. The firm has “Buy” rating given on Wednesday, November 4 by Cantor Fitzgerald. Roth Capital maintained the shares of BDSI in a report on Friday, March 11 with “Buy” rating. Janney Capital initiated BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Tuesday, October 27 with “Neutral” rating.

Insitutional Activity: The institutional sentiment increased to 0.82 in 2016 Q2. Its up 0.25, from 0.57 in 2016Q1. The ratio improved, as 30 funds sold all BioDelivery Sciences International, Inc. shares owned while 30 reduced positions. 13 funds bought stakes while 21 increased positions. They now own 29.37 million shares or 23.18% less from 38.23 million shares in 2016Q1.

Us Bancshares De owns 200 shares or 0% of their US portfolio. Millennium Mngmt Ltd has invested 0.01% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). The Pennsylvania-based Valley National Advisers has invested 0.01% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Price T Rowe Assoc Md reported 31,500 shares or 0% of all its holdings. The Kansas-based Creative Planning has invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). The California-based Engaged Cap Limited Liability Co has invested 1.56% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Parametric Port Ltd accumulated 0% or 807,097 shares. Tiverton Asset Mngmt Limited Liability accumulated 0.11% or 58,949 shares. Fincl Bank Of Montreal Can has 698,290 shares for 0% of their US portfolio. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. Renaissance Technology Ltd Liability Co owns 1.71M shares or 0.01% of their US portfolio. Ameriprise Financial Inc has invested 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Sabby Mngmt Limited Company last reported 785,799 shares in the company. Moreover, Deutsche Retail Bank Ag has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 1.40M shares. Laurion Capital Management Lp last reported 0% of its portfolio in the stock.

Insider Transactions: Since August 11, 2016, the stock had 2 insider purchases, and 4 sales for $436,107 net activity. Feinberg Barry I bought $6,375 worth of stock. 16,000 BioDelivery Sciences International, Inc. (NASDAQ:BDSI) shares with value of $41,120 were sold by STONE WILLIAM B. De Paolantonio Ernest Robert also sold $36,112 worth of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Wednesday, September 21. ODONNELL FRANCIS E JR sold $256,500 worth of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Thursday, September 22. Shares for $114,360 were sold by Vasisht Niraj.

About 200 shares traded hands. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has declined 52.83% since April 22, 2016 and is downtrending. It has underperformed by 58.24% the S&P500.

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The company has a market cap of $91.92 million. The Firm develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. It currently has negative earnings. The Firm develops pharmaceutical products aimed principally in the areas of pain management and addiction.

According to Zacks Investment Research, “BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any process, substance, or combination thereof, that delivers drugs into the body.”

Analysts await BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report earnings on March, 9. They expect $-0.27 EPS, down 235.00% or $0.47 from last year’s $0.2 per share. After $-0.30 actual EPS reported by BioDelivery Sciences International, Inc. for the previous quarter, Wall Street now forecasts -10.00% EPS growth.

Another recent and important BioDelivery Sciences International, Inc. (NASDAQ:BDSI) news was published by Prnewswire.com which published an article titled: “BioDelivery Sciences to Present at the 28th Annual Piper Jaffray Healthcare ..” on November 23, 2016.

BDSI Company Profile

BioDelivery Sciences International, Inc., incorporated on April 18, 2002, is a specialty pharmaceutical company. The Firm develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Firm develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>